Brokerage Firm Rating Update on EXACT Sciences Corporation (EXAS)

EXACT Sciences Corporation (EXAS) : 5 brokerage houses believe that EXACT Sciences Corporation (EXAS) is a Strong Buy at current levels. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on EXACT Sciences Corporation (EXAS). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 10 Wall Street Analysts endorse the stock as a Buy with a rating of 2.

EXACT Sciences Corporation (EXAS) has been rated by 9 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $26 and the lowest price target forecast is $8. The average forecast of all the analysts is $15.78 and the expected standard deviation is $5.91.


For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Goldman Sachs maintains its ratings on EXACT Sciences Corporation (NASDAQ:EXAS). In the latest research report, Goldman Sachs raises the target price from $16 per share to $18 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on August 15, 2016.

EXACT Sciences Corporation (NASDAQ:EXAS): The stock opened at $19.08 and touched an intraday high of $20.05 on Wednesday. During the day, the stock corrected to an intraday low of $19.08, however, the bulls stepped in and pushed the price higher to close in the green at $19.43 with a gain of 2.16% for the day. The total traded volume for the day was 2,605,594. The stock had closed at $19.02 in the previous trading session.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.